Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study - Test2 - elhamkhani - TriplyDB

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

http://www.wikidata.org/entity/Q28287750

about

Children's Oncology Group's 2013 blueprint for research: radiation oncology Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement.Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031 Pediatric lymphomas and histiocytic disorders of childhood Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussion Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.Advances in paediatric cancer treatment Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up.Adolescents with Hodgkin lymphoma: old children or young adults?Management of children with high-risk Hodgkin lymphoma.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.FDG PET/CT in children and adolescents with lymphoma.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma.Therapeutic approaches to haematological malignancies in adolescents and young adults.Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma.Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.Prognostic Biomarkers for Hodgkin Lymphoma.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study.Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.Management of Hodgkins Lymphoma: ICMR Consensus Document.Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells.Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.

P2860

Q27023346-360C8F6C-B63D-4DE5-86B8-CF7F2524B72B Q28486108-384BB49A-1A92-4E64-B367-6AF533439966 Q30248284-1FCCA91D-F7BA-496A-B8C0-8FE1FE81464A Q30313537-C088EF1C-905C-4D2D-82D0-EAE09A20CA75 Q30313852-33D55151-29AE-4CCB-B069-DD314426CD7B Q34451778-0288180D-28E1-43FC-A8D0-2BD3672FF31D Q34605894-632325AC-0448-4807-98A0-663265AC1A51 Q34664424-78F66A52-B501-476A-93A2-CE0F22C6481C Q34707420-2BA814AA-4797-4494-84B7-9AC1D6CFA8C2 Q35126260-6EC74D17-7BD8-4B12-951A-79CF48F105B3 Q35924909-819330F9-F792-4284-AD9F-3C63E8904137 Q36222944-8DC26611-E442-4FF2-AA6D-510FF5D2BA70 Q36309826-EACFC641-FC78-4FF2-948D-7B0E6EA63E90 Q36479283-B0C52E6C-27CA-4DE5-BCE9-03B1BD0D9F60 Q36508230-B197E0CF-D47C-4BD2-93D5-8DCD78CBB949 Q36508630-F66AD904-FC93-43C5-AE0E-20EC49879DB8 Q37627536-9F26EFC1-5C70-467E-8271-E72C7FF5BB5F Q37968278-084C7950-1496-44BC-9201-53551DB3D29A Q37970408-F27F76D7-F91C-4D79-B37E-EC2C71AAE13D Q38068839-2D1FDF16-2E67-4E10-8CDD-D2BBBC979C0E Q38092706-74716D5D-ADEC-408D-8DE1-9B42D2D64A7D Q38112088-53670741-F162-42BC-ACA0-1AAB96C9BA0D Q38131410-D7295629-FE25-43F7-A763-78F540B12FB5 Q38134399-6803F18B-CDE6-48CD-81A8-31243040F150 Q38185983-AEC96C0C-F758-4F96-9C5D-C370B37D4BC6 Q38195016-6DCD04F0-BDE1-4534-AFA2-FBA21F2FD8DC Q38199088-8B1E86E0-974A-4C6B-A250-6E0B614A2D19 Q38396485-6472219E-B506-4C99-B619-9F14357ACAE2 Q38588503-841420DA-574E-47B5-81F8-99D591C6F913 Q38775871-09885DD0-2C5E-4E36-BB9C-28576BCC9781 Q38807893-1EC3D771-D2AD-4408-B7EF-CAF3C5C1BE6D Q39066137-6819F32E-D568-4266-8188-D12A9EA0A34D Q39129713-1CE8D8FE-A662-4E04-A146-CB1A6B430CDE Q39193590-4D78031C-F356-40E6-9ED7-2E54783C404B Q39208309-36E05FF4-A009-4D30-BC6E-2B1F52BDB7B3 Q39244757-4532C1BA-D6C0-4999-BA73-A389DAC43478 Q39386056-4D3BAA79-C55A-4869-99F6-5154EDD82EAC Q39518368-53CE726F-6F29-492C-BA0D-59F4A520F34D Q39539001-46F23EE1-7726-411D-8C9F-17F156D041C8 Q40033092-8CAF2FE0-9816-4C86-B875-EEF492208EB3

P2860

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

http://www.wikidata.org/entity/Q28287750

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@ast

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@en

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@nl

type

label

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@ast

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@en

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@nl

prefLabel

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@ast

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@en

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@nl

P1433

Q28287750-CB05B2A4-653A-40E6-955A-09F45D6316C6

P1476

Q28287750-08C0BB38-FC54-42CE-922B-38EBCA24024D

P2093

Q28287750-0562DEFA-0EC8-4A61-A37E-B580AEF427BC

Q28287750-36895E02-F6B8-4140-A527-4FEE36497530

Q28287750-39CED669-40DE-4117-8999-C3460F71BC37

Q28287750-3D16A1CA-C902-4475-ACF1-FF1505F66E8A

Q28287750-3D9EFFA5-DCE9-4E17-AD6E-1AAF1B8A6E0A

Q28287750-445B7C3F-8F32-466D-BDF0-BFD52C95922A

Q28287750-58A58B5F-FE72-4422-8AC6-6950D4E55D7F

Q28287750-66B39D3A-2D5E-489C-B64B-548E2C786A6C

Q28287750-745A16C8-FD90-4541-8369-35EECD255C78

Q28287750-7683CEB2-D792-48C8-A3BE-4FC2E7DBA72D

P304

Q28287750-7CD1E672-9494-4A42-B8CC-69CCDF87C737

P31

Q28287750-70C73213-6DA6-4998-BF77-D59F8A00BCF6

P356

Q28287750-AEC4AE0A-50BC-4421-A508-B2D4D47AFBCA

P407

Q28287750-AAC98F22-6AFA-4B8B-AB27-A700F74D6030

P433

Q28287750-4CFE22C7-B194-4C7F-A8DB-095361366787

P478

Q28287750-71F52257-ED73-4601-8E31-2FB6B3686DFD

P50

Q28287750-5599BD8A-369A-42BB-88BC-F54F06E8E8C7

Q28287750-674FA5F2-A0B6-449F-8B54-50B538194A60

Q28287750-B1D80F42-F6AA-462C-A777-F24A24CA6F76

P577

Q28287750-4611002A-5E02-4549-9C4B-88B62F82713D

P698

Q28287750-4E8530F0-92A3-43A4-8230-E84032FF0046

P921

Q28287750-F304A2B8-1DEC-4F7F-AA00-43D59E52B337

P356

JCO.2009.26.9381

P1433

Journal of Clinical Oncology

P1476

Procarbazine-free OEPA-COPDAC ...... mphoma: the GPOH-HD-2002 study

@en

P2093

Antje Voigt

http://www.w3.org/2001/XMLSchema#string

Christine Mauz-Körholz

http://www.w3.org/2001/XMLSchema#string

Constanze Vilser

http://www.w3.org/2001/XMLSchema#string

Dieter Körholz

http://www.w3.org/2001/XMLSchema#string

Dirk Vordermark

http://www.w3.org/2001/XMLSchema#string

Eva Bergsträsser

http://www.w3.org/2001/XMLSchema#string

Georg Mann

http://www.w3.org/2001/XMLSchema#string

Harald Stein

http://www.w3.org/2001/XMLSchema#string

Jonas Karlén

http://www.w3.org/2001/XMLSchema#string

Karin Dieckmann

http://www.w3.org/2001/XMLSchema#string

P304

3680-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.9381

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Hasenclever

Alexander Fosså

P577

2010-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20625128

http://www.w3.org/2001/XMLSchema#string

P921